Abstract：
OBJECTIVE: Plasma rich in growth factors (PRGF) technology creates blood-derived products with growth factors that promote wound healing and regeneration. The goal of this study was to assess the potential role of PRGF products as wound modulators in trabeculectomy. Our premise is that due to PRGF\'s regenerative and antifibrotic properties, its use in trabeculectomy may produce a more physiological bleb, without altering IOP reduction.
METHODS: A retrospective, longitudinal study was conducted in a Hospital in Portugal. Patients with eyes with open angle glaucoma were included. Trabeculectomy was performed on all patients using PRGF membrane (mPRGF) under the conjunctiva, as adjuvant. Data regarding patients\' demographics and number of medications used, was collected. Intraocular pressure (IOP) before surgery, 8 days, 1 month, 3 month, 6 month, 9 month and 1 year after surgery was recorded. Bleb morphology was classified according to Moorfields Bleb Grading System 6 months after surgery.
RESULTS: Nine eyes of 9 patients were enrolled. Mean age was 71 ± 5.1 years old. Six were male. Mean IOP decreased from 24.0 ± 8.8 mmHg pre-surgery to 12.9 ± 2.6 mmHg at one year follow-up. The number of hypotensive drugs (mean ± SD) was 4.3 ± 0.9 preoperatively and 0.8 ± 1.1 at 1-year. Complete success was defined as IOP equal to or less than 21 mm Hg without ocular hypotensive medications and qualified success as IOP equal to or less than 21 mm Hg with medications. Complete success was 66.7% and qualified success was 100% at 1 year follow-up.
CONCLUSIONS: In our study, trabeculectomy with mPRGF demonstrated both safety and efficacy. Low values of bleb height (1.6 ± 0.8) were recorded. mPRGF could improve wound healing and produce a more well-tolerated, favourable bleb, avoiding antimetabolite complications.
METHODS: A retrospective, longitudinal study was conducted in a Hospital in Portugal. Patients with eyes with open angle glaucoma were included. Trabeculectomy was performed on all patients using PRGF membrane (mPRGF) under the conjunctiva, as adjuvant. Data regarding patients\' demographics and number of medications used, was collected. Intraocular pressure (IOP) before surgery, 8 days, 1 month, 3 month, 6 month, 9 month and 1 year after surgery was recorded. Bleb morphology was classified according to Moorfields Bleb Grading System 6 months after surgery.
RESULTS: Nine eyes of 9 patients were enrolled. Mean age was 71 ± 5.1 years old. Six were male. Mean IOP decreased from 24.0 ± 8.8 mmHg pre-surgery to 12.9 ± 2.6 mmHg at one year follow-up. The number of hypotensive drugs (mean ± SD) was 4.3 ± 0.9 preoperatively and 0.8 ± 1.1 at 1-year. Complete success was defined as IOP equal to or less than 21 mm Hg without ocular hypotensive medications and qualified success as IOP equal to or less than 21 mm Hg with medications. Complete success was 66.7% and qualified success was 100% at 1 year follow-up.
CONCLUSIONS: In our study, trabeculectomy with mPRGF demonstrated both safety and efficacy. Low values of bleb height (1.6 ± 0.8) were recorded. mPRGF could improve wound healing and produce a more well-tolerated, favourable bleb, avoiding antimetabolite complications.
摘要：
目的：富含生长因子的血浆（PRGF）技术可产生具有促进伤口愈合和再生的生长因子的血液衍生产品。这项研究的目的是评估PRGF产物作为小梁切除术中伤口调节剂的潜在作用。我们的前提是，由于PRGF的再生和抗纤维化特性，它在小梁切除术中的使用可能会产生更生理性的气泡，不改变IOP降低。
方法：回顾性研究，纵向研究在葡萄牙的一家医院进行.包括患有开角型青光眼的患者。所有患者在结膜下使用PRGF膜（mPRGF）进行小梁切除术，作为佐剂。有关患者人口统计学和使用药物数量的数据，被收集。术前眼压(IOP),8天,1个月,3个月,6个月,记录术后9个月和1年。术后6个月，根据MoorfieldsBleb分级系统对Bleb形态进行分类。
结果：纳入9例患者的9只眼。平均年龄71±5.1岁。六个是男性。平均眼压从术前24.0±8.8mmHg下降至1年随访时的12.9±2.6mmHg。术前降压药物的数量（平均值±SD）为4.3±0.9，1年为0.8±1.1。完全成功被定义为眼压等于或小于21mmHg，而眼压等于或小于21mmHg，而眼压等于或小于21mmHg。1年随访时，完全成功率为66.7%，合格成功率为100%。
结论：在我们的研究中，mPRGF小梁切除术证明了安全性和有效性。记录低泡高度值(1.6±0.8)。mPRGF可以改善伤口愈合，产生更良好的耐受性，有利的气泡，避免抗代谢并发症。
方法：回顾性研究，纵向研究在葡萄牙的一家医院进行.包括患有开角型青光眼的患者。所有患者在结膜下使用PRGF膜（mPRGF）进行小梁切除术，作为佐剂。有关患者人口统计学和使用药物数量的数据，被收集。术前眼压(IOP),8天,1个月,3个月,6个月,记录术后9个月和1年。术后6个月，根据MoorfieldsBleb分级系统对Bleb形态进行分类。
结果：纳入9例患者的9只眼。平均年龄71±5.1岁。六个是男性。平均眼压从术前24.0±8.8mmHg下降至1年随访时的12.9±2.6mmHg。术前降压药物的数量（平均值±SD）为4.3±0.9，1年为0.8±1.1。完全成功被定义为眼压等于或小于21mmHg，而眼压等于或小于21mmHg，而眼压等于或小于21mmHg。1年随访时，完全成功率为66.7%，合格成功率为100%。
结论：在我们的研究中，mPRGF小梁切除术证明了安全性和有效性。记录低泡高度值(1.6±0.8)。mPRGF可以改善伤口愈合，产生更良好的耐受性，有利的气泡，避免抗代谢并发症。
